Intravenous Paracetamol and Patent Ductus Arteriosus Closure

Document Type : Original Article

Authors

1 Pediatric Cardiology Division, Department of Child Health, Medical School, Syiah Kuala University, Zainoel Abidin Hospital, Banda Aceh, Indonesia

2 Neonatology Division, Department of Child Health, Medical School, Syiah Kuala University, Zainoel Abidin Hospital, Banda Aceh, Indonesia .

3 Neonatology Division, Department of Child Health, Medical School, Syiah Kuala University, Zainoel Abidin Hospital, Banda Aceh, Indonesia

Abstract

Background: Standard medical treatments for patent ductus arteriosus (PDA) closure are, including indomethacin/ibuprofen and surgical ligation. Nowadays, a new strategy to close PDA is the use of paracetamol. The present study aimed to describe the use of intravenous (IV) paracetamol for PDA closure in neonates who present a contraindication to ibuprofen or ibuprofen failure with no possibility to perform surgical ligation due to major instability.
Methods: The present study was conducted from January to December 2017 in the neonatal intensive care unit of Dr. Zainoel Abidin Hospital and Harapan Bunda Hospital, Banda Aceh, Indonesia, on neonates with hemodynamic significant PDA (hsPDA). All the subjects received IV paracetamol (15 mg/kg every 6 h) for 3 days. Thereafter, the ductus was evaluated by echocardiography on the 5th day after the regiment.
Results: A total of 72 neonates were diagnosed with hsPDA and their average of gestational age was 34.26 weeks and their average of birth weight was 1945.69 g for 39 (54.2%) female neonates, 33 (45.8%) male neonates, 45 (62.5%) premature infants, and 27 (37.5%) full-term infants. About 26 (36.1%) infants had a closed PDAs on the 5th days of evaluation, 11 (15.3%) infants had regiment twice for closed PDA at the 10th days of evaluation, and 35 (48.6%) neonates had more closed PDA after three or four regiments. Successful closure with paracetamol was achieved in 51(70.8%) neonates, while 21 (29.2%) neonates failed the PDA closure.
Conclusion: Based on the findings of the present study, IV paracetamol appears to be reasonably effective for PDA closure in both preterm and term infants. This should be the first-line of therapy choice when there are contraindications for the treatment with ibuprofen.

Keywords

References

1. Agarwal R, Deorari AK, Paul VK. Patent ductus arteriosus in preterm neonates. Indian J Pediatr. 2008; 75(3):277.
2. Allegaert K, Anderson B, Simons S, van Overmeire B. Paracetamol to induce ductus arteriosus closure: is it valid? Arch Dis Child. 2013; 98(6):462-6.
3. Brunner B, Hoeck M, Schermer E, Streif W, Kiechl-Kohlendorfer U. Patent ductus arteriosus low platelets, cyclooxygenase inhibitors and intraventricular hemorrhage in very low birth weight preterm infants. J Pediatr. 2013; 163(1):23-8.
4. Weisz DE, More K, McNamara PJ, Shah PS. PDA ligation and health outcomes: a meta-analysis. Pediatrics. 2014; 133(4):e1024-46.
5. Hammerman C, Bin-Nun A, Markovitch E, Schimmel MS, Kaplan M, Fink D. Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics. 2011; 128(6):e1618-21.
6. Dani C, Poggi CH, Mosca F, Schena F, Lista G, Ramenghi L, et al. Efficacy and safety of IV paracetamol in comparison to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: study protocol for a randomized control trial. Trials. 2016; 17:182.
7. El-Khuffash A, Amish J, Corcoran D, Shah P, Hooper CH, Brown N, et al. Efficacy of paracetamol on patent ductus arteriosus closure may be dose dependent: evidence from human and murine studies. Pediatr Res. 2014; 76(3):238-44.
8. Oncel MY, Yurttutan S, Uras N, Altug N, Ozdemir R, Ekmen S, et al. An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants. Arch Dis Child Fetal Neonatal Ed. 2013; 98(1):F94.
9. Oncel MY, Yurttutan S, Degirmencioglu H, Uras N, Altug N, Erdeve O, et al. IV paracetamol treatment in the management of patent ductus arteriosus in extremely low birth weight infants. Neonatology. 2013; 103(3):166-9.
10. Sinha R, Negi V, Dalal SS. An interesting observation of PDA closure with oral paracetamol in preterm neonates. J Clin Neonatol. 2013; 2(1):30-2.
11. Roofthooft DW, van Beynum IM, Helbing WA, Reiss IK, Simons SH. Paracetamol for ductus arteriosus closure: not always a success story. Concerning the article by M.Y. Oncel et al: IV paracetamol treatment in the management of patent ductus arteriosus in extremely low birth weight infants [Neonatology
2013;103:166-169]. Neonatology. 2013; 104(3):170.
12. Tekgündüz KS, Ceviz N, Caner I, Olgun H, Demirelli Y, Yolcu C, et al. IV paracetamol with a lower dose is also effective for the treatment of patent ductus arteriosus in pre-term infants. Cardiol Young. 2015; 25(6):1060-4.
13. Oncel MY, Eras Z, Uras N, Canpolat FE, Erdeve O, Oguz SS. Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. Am J Perinatol. 2017; 34(12):1185-9.
14. Hermes-DeSantis ER, Clyman RI. Patent ductus arteriosus: pathophysiology and management. J Perinatol. 2006; 26(Suppl 1):14-8.
Iranian Journal of Neonatology
Volume 11, Issue 1
January 2020
Pages 31-35

Files

Share

How to cite

Statistics